GT200800151A - Inhibidores de 11-beta-hsd1 - Google Patents
Inhibidores de 11-beta-hsd1Info
- Publication number
- GT200800151A GT200800151A GT200800151A GT200800151A GT200800151A GT 200800151 A GT200800151 A GT 200800151A GT 200800151 A GT200800151 A GT 200800151A GT 200800151 A GT200800151 A GT 200800151A GT 200800151 A GT200800151 A GT 200800151A
- Authority
- GT
- Guatemala
- Prior art keywords
- beta
- hsd1 inhibitors
- hsd1
- discontrolled
- excessed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Abstract
SE PRESENTAN COMPUESTOS DERIVADOS DE ARILO, QUE ACTUAN EN LA INHIBICION DE 11-BETA-HSD1, ASI COMO METODOS PARA TRATAR LA OBESIDAD, EL SINDROME X, DIABETES TIPO 2, Y UNA ENFERMEDAD O CONDICION MEDIADA POR CANTIDADES EN EXCESO O DESCONTROLADAS DE CORTISOL Y/O OTROS CORTICOSTEROIDES. T2008
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77126206P | 2006-02-07 | 2006-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200800151A true GT200800151A (es) | 2008-11-03 |
Family
ID=38236242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200800151A GT200800151A (es) | 2006-02-07 | 2008-08-07 | Inhibidores de 11-beta-hsd1 |
Country Status (18)
Country | Link |
---|---|
US (2) | US7632838B2 (es) |
EP (1) | EP1981848A2 (es) |
JP (1) | JP2009526059A (es) |
KR (1) | KR20080093072A (es) |
CN (1) | CN101400653A (es) |
AR (1) | AR059355A1 (es) |
AU (1) | AU2007212429A1 (es) |
BR (1) | BRPI0707537A2 (es) |
CA (1) | CA2641609A1 (es) |
CR (1) | CR10186A (es) |
GT (1) | GT200800151A (es) |
IL (1) | IL193157A0 (es) |
NO (1) | NO20083492L (es) |
PA (1) | PA8713501A1 (es) |
PE (1) | PE20071232A1 (es) |
RU (1) | RU2008132333A (es) |
TW (1) | TW200800898A (es) |
WO (1) | WO2007092435A2 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2004619A1 (en) * | 2006-03-23 | 2008-12-24 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
WO2007135427A1 (en) * | 2006-05-23 | 2007-11-29 | Astrazeneca Ab | 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors |
CL2007003223A1 (es) * | 2006-11-10 | 2008-01-11 | Wyeth Corp | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. |
MX2009008368A (es) * | 2007-02-07 | 2009-08-12 | Wyeth Corp | Metodos para preparar aminas halogenadas. |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CN101801954B (zh) | 2007-09-20 | 2013-10-09 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
WO2009051244A1 (ja) | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
CN101597278B (zh) | 2008-06-04 | 2013-04-17 | 中国中化股份有限公司 | 酰胺类化合物及其制备与应用 |
GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
AR074318A1 (es) | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
WO2010141550A2 (en) * | 2009-06-04 | 2010-12-09 | Wyeth Llc | 11-beta hsd1 inhibitors |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP5972367B2 (ja) * | 2011-07-01 | 2016-08-17 | リマインド・ナムローゼ・フエンノートシャップRemynd Nv | 神経変性疾患の治療に有用な1,2,4−チアジアゾール−5−イルピペラジン誘導体 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
JP6339416B2 (ja) * | 2014-05-28 | 2018-06-06 | 国立大学法人 名古屋工業大学 | 光学活性スルホンアミド誘導体の製造方法 |
CN104974084A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
US11358959B2 (en) * | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
SG10202113146UA (en) | 2017-05-25 | 2021-12-30 | Araxes Pharma Llc | Covalent inhibitors of kras |
CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
GB201713780D0 (en) * | 2017-08-29 | 2017-10-11 | E-Therapeutics Plc | Modulators of hedgehog (Hh) signalling pathway |
CA3112326A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
US20220024891A1 (en) * | 2018-12-04 | 2022-01-27 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer |
CN111943893A (zh) * | 2019-05-17 | 2020-11-17 | 南京爱德程医药科技有限公司 | 4,7-二氮杂螺[2.5]辛烷类化合物的合成方法 |
SI3770201T1 (sl) * | 2019-07-22 | 2023-09-29 | Evonik Operations Gmbh | Polimerna anionsko prevodna membrana |
JP7417715B2 (ja) | 2019-09-26 | 2024-01-18 | ノバルティス アーゲー | 抗ウイルスピラゾロピリジノン化合物 |
EP4081509A4 (en) * | 2019-12-24 | 2024-01-03 | Zydus Lifesciences Ltd | NOVEL COMPOUNDS SUITABLE FOR TREATING DYSLIPIDEMIA |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2875205A (en) * | 1959-02-24 | Chj-chj | ||
ZA813332B (en) * | 1980-06-21 | 1982-05-26 | Pfizer | Larvicides and isecticides |
JPS6081168A (ja) * | 1983-10-13 | 1985-05-09 | Asahi Chem Ind Co Ltd | アミジン誘導体 |
FR2553414B1 (fr) * | 1983-10-18 | 1986-08-14 | Choay Sa | Nouveaux benzenesulfonamides n-cyclises, leur procede de preparation et leur utilisation comme substance active de compositions pharmaceutiques |
US4857644A (en) | 1988-06-09 | 1989-08-15 | American Home Products Corporation | Aryl sulfonopiperazines as anti-inflammatory agents |
WO1993012086A1 (en) * | 1991-12-11 | 1993-06-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivative |
EP0661266A1 (en) | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
EP0891334A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0952842A2 (en) | 1996-04-18 | 1999-11-03 | Merck & Co., Inc. | A method of treating cancer |
WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
CN1129581C (zh) | 1998-09-22 | 2003-12-03 | 山之内制药株式会社 | 氰基苯基衍生物 |
AU1230100A (en) | 1998-10-29 | 2000-05-22 | Merck & Co., Inc. | A method of treating endometriosis |
US6465468B1 (en) * | 1999-03-22 | 2002-10-15 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
JP2001328938A (ja) | 2000-03-17 | 2001-11-27 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体を有効成分とする医薬 |
JP2001261657A (ja) | 2000-03-17 | 2001-09-26 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体 |
EP1311934B1 (de) * | 2000-06-16 | 2005-11-30 | BAUMÜLLER ANLAGEN-SYSTEMTECHNIK GmbH & Co. | Verfahren zum automatischen erzeugen mehrerer elektrischer impulse anhand numerischer vorgabewerte, insbesondere als inkrementalgeber-nachbildung |
EP1351946A2 (en) | 2000-09-01 | 2003-10-15 | Icos Corporation | Materials and methods to potentiate cancer treatment |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
MXPA04001607A (es) | 2001-08-21 | 2004-07-08 | Merck Sharp & Dohme | Ciclohexilsulfonas novedosas. |
WO2003044000A1 (en) | 2001-11-22 | 2003-05-30 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
EP1461333A1 (en) | 2001-11-22 | 2004-09-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
NZ534830A (en) | 2002-03-13 | 2005-08-26 | Janssen Pharmaceutica Nv | Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases |
JP2005533858A (ja) | 2002-07-27 | 2005-11-10 | アストラゼネカ アクチボラグ | 化合物 |
AU2003269242A1 (en) | 2002-10-11 | 2004-05-04 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
JP2006514102A (ja) | 2002-11-07 | 2006-04-27 | アストラゼネカ アクチボラグ | 2−オキソ−エタンスルホンアミド誘導体 |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
KR20060036105A (ko) | 2003-07-29 | 2006-04-27 | 제논 파마슈티칼스 인크. | 피리딜 유도체 및 그의 치료제로서의 용도 |
PL1651620T3 (pl) | 2003-07-30 | 2012-04-30 | Xenon Pharmaceuticals Inc | Pochodne piperazyny i ich zastosowanie jako środków terapeutycznych |
ES2397389T3 (es) | 2003-07-30 | 2013-03-06 | Xenon Pharmaceuticals Inc. | Derivados de piridilo y su uso como agentes terapéuticos |
US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
JP2007515490A (ja) | 2003-12-22 | 2007-06-14 | アムジェン インコーポレーティッド | アリールスルホンアミド化合物およびそれに関連する使用法 |
EP1711477A4 (en) | 2004-01-26 | 2009-06-10 | Merck & Co Inc | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 |
WO2005089502A2 (en) | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
AR048523A1 (es) | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
CA2561525A1 (en) | 2004-04-14 | 2005-11-24 | Amgen, Inc. | Aryl sulfones and uses related thereto |
JP2007533749A (ja) * | 2004-04-20 | 2007-11-22 | アムゲン インコーポレイティッド | アリールスルホンアミドおよびそれに関連する使用方法 |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
CA2567343A1 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
MXPA06014572A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Compuestos amido y su uso como farmaceuticos. |
JP2008504279A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
CA2584502A1 (en) | 2004-06-24 | 2006-01-05 | Incyte Corporation | 2-methylpropanamides and their use as pharmaceuticals |
DK1763517T3 (da) * | 2004-06-28 | 2011-06-06 | Hoffmann La Roche | Pyrimidinderivater som 11beta-HSD1-inhibitorer |
CA2570183A1 (en) | 2004-06-30 | 2006-01-12 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
DE602005008079D1 (de) * | 2004-07-28 | 2008-08-21 | Hoffmann La Roche | Aryl-pyridinderivate als 11-beta-hsd1-hemmer |
US20060025445A1 (en) | 2004-08-02 | 2006-02-02 | Xiang Jason S | 11-Beta HSD1 inhibitors |
GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
WO2006105127A2 (en) | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
JP2009514859A (ja) * | 2005-11-03 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 置換ニコチンアミド化合物 |
EP1968962A2 (en) | 2005-12-14 | 2008-09-17 | Amgen Inc. | Diaza heterocyclic sulfonamide derivatives and their uses |
AU2006331882A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists |
-
2007
- 2007-02-07 PA PA20078713501A patent/PA8713501A1/es unknown
- 2007-02-07 WO PCT/US2007/003134 patent/WO2007092435A2/en active Application Filing
- 2007-02-07 KR KR1020087021870A patent/KR20080093072A/ko not_active Application Discontinuation
- 2007-02-07 EP EP07717205A patent/EP1981848A2/en not_active Withdrawn
- 2007-02-07 JP JP2008554299A patent/JP2009526059A/ja not_active Withdrawn
- 2007-02-07 RU RU2008132333/04A patent/RU2008132333A/ru not_active Application Discontinuation
- 2007-02-07 PE PE2007000130A patent/PE20071232A1/es not_active Application Discontinuation
- 2007-02-07 CA CA002641609A patent/CA2641609A1/en not_active Abandoned
- 2007-02-07 BR BRPI0707537-5A patent/BRPI0707537A2/pt not_active IP Right Cessation
- 2007-02-07 AU AU2007212429A patent/AU2007212429A1/en not_active Abandoned
- 2007-02-07 CN CNA2007800088400A patent/CN101400653A/zh active Pending
- 2007-02-07 US US11/703,522 patent/US7632838B2/en not_active Expired - Fee Related
- 2007-02-07 TW TW096104455A patent/TW200800898A/zh unknown
- 2007-02-07 AR ARP070100510A patent/AR059355A1/es unknown
-
2008
- 2008-07-30 CR CR10186A patent/CR10186A/es not_active Application Discontinuation
- 2008-07-31 IL IL193157A patent/IL193157A0/en unknown
- 2008-08-07 GT GT200800151A patent/GT200800151A/es unknown
- 2008-08-12 NO NO20083492A patent/NO20083492L/no not_active Application Discontinuation
-
2009
- 2009-08-11 US US12/539,232 patent/US20100029648A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2007212429A1 (en) | 2007-08-16 |
TW200800898A (en) | 2008-01-01 |
RU2008132333A (ru) | 2010-03-20 |
IL193157A0 (en) | 2009-02-11 |
PE20071232A1 (es) | 2008-02-18 |
CN101400653A (zh) | 2009-04-01 |
EP1981848A2 (en) | 2008-10-22 |
US20100029648A1 (en) | 2010-02-04 |
US20070219198A1 (en) | 2007-09-20 |
CA2641609A1 (en) | 2007-08-16 |
KR20080093072A (ko) | 2008-10-17 |
NO20083492L (no) | 2008-10-28 |
AR059355A1 (es) | 2008-03-26 |
JP2009526059A (ja) | 2009-07-16 |
BRPI0707537A2 (pt) | 2011-05-03 |
WO2007092435A2 (en) | 2007-08-16 |
CR10186A (es) | 2008-10-29 |
WO2007092435A3 (en) | 2007-12-27 |
PA8713501A1 (es) | 2009-09-17 |
US7632838B2 (en) | 2009-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200800151A (es) | Inhibidores de 11-beta-hsd1 | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
HN2008001720A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina | |
CR10680A (es) | Composiciones de inhibidores de chk1 | |
CL2008003653A1 (es) | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. | |
CR11299A (es) | Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis | |
MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
TN2009000521A1 (en) | Rnai inhibition of alpha-enac expression | |
MY150602A (en) | Subtituted-quinoxaline-type piperidine compounds and the uses thereof | |
CL2010001474A1 (es) | Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares. | |
BRPI0811119A2 (pt) | Métodos de cimentação, e para acelerar o tempo de cura de uma composição de cimento, composição de cimento de poço, métodos para tratar uma formação subterrânea, e para utilizar nanopartículas em um fluído de tratamento de poço, e, fluido de tratamento de poço. | |
EA200870385A1 (ru) | Ингибирование токсичности альфа-синуклеина | |
CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
CL2007003176A1 (es) | Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis. | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
CL2008001005A1 (es) | Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv. | |
MX2009010960A (es) | Compuestos heterociclicos y sus metodos de uso. | |
GT200900065A (es) | Derivado de 2-piridincarboxamida que tiene efecto activador de gk | |
DOP2010000302A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
MX2009013676A (es) | Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa. | |
CL2011003079A1 (es) | Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes. | |
CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
CL2007003467A1 (es) | Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion |